Prolyl Hydroxylase Inhibitor Compounds for HIF-1α Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that inhibit prolyl hydroxylase enzymes to regulate HIF-1α concentration in cells, thereby stimulating angiogenic and erythropoietic responses to treat conditions like peripheral vascular disease, coronary artery disease, ischemia, and anemia.
Innovation Solution
Substituted aryl or heteroaryl amide compounds are developed to inhibit HIF-1α prolyl hydroxylase, enhancing blood flow, oxygen delivery, and energy utilization in ischemic tissues, and upregulating erythropoietin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prolyl hydroxylase enzymes are inhibited to regulate HIF-1α concentration, then angiogenic and erythropoietic responses are stimulated, but the complexity of the therapeutic approach increases
Solution Approach 1:
The prolyl hydroxylase enzyme is segmented into three distinct isoforms (PHD1, PHD2, PHD3) with different tissue distributions and functional roles. The patent develops selective inhibitors for each isoform, allowing targeted therapy that stimulates angiogenic responses through PHD2 inhibition while avoiding unwanted effects from non-selective inhibition of all isoforms.
Solution Approach 2:
The patent applies local quality by creating compounds with different selectivity profiles for specific PHD isoforms in different tissue contexts. For example, PHD2-selective inhibitors are used preferentially in ischemic diseases where angiogenesis is desired, while PHD3-selective inhibitors are used in cancer therapy where HIF degradation is needed. This localized approach optimizes therapeutic effectiveness while minimizing off-target effects.
2Use of energy by moving object
If HIF-1α concentration is increased through enzyme inhibition, then oxygen delivery and energy utilization improve, but the risk of harmful side effects increases
Solution Approach 1:
The patent employs feedback mechanisms by designing compounds that respond to cellular oxygen levels and HIF-1α accumulation. The inhibitors are activated specifically under hypoxic conditions where they are most needed, and their effects are self-regulating through the natural feedback loops of HIF-mediated gene expression. This ensures improved energy utilization while minimizing side effects through context-dependent activation.
Solution Approach 2:
The patent utilizes parameter changes by developing compounds with optimized pharmacokinetic and pharmacodynamic properties. The inhibitors are designed with specific binding affinities, cellular permeability characteristics, and metabolic stability parameters that allow them to achieve therapeutic HIF-1α stabilization while maintaining safety margins. Dose-dependent effects are exploited to achieve optimal therapeutic windows.
3Reliability
If selective PHD2 inhibitors are used to stimulate angiogenesis, then therapeutic benefits are achieved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent uses proline and hydroxyproline derivatives as intermediary structures that naturally bind to the prolyl hydroxylase active site. These intermediary scaffolds are then modified with various aromatic and heterocyclic groups to create selective PHD2 inhibitors. The intermediary approach allows for systematic structure-activity relationship studies and simplifies the synthesis of selective inhibitors compared to de novo design.
Solution Approach 2:
The patent achieves selectivity through parameter changes in the molecular structure, particularly in the aromatic substituents and linker regions of the inhibitors. Small changes in substituent position, size, or electronic properties significantly affect binding selectivity for PHD2 versus other isoforms. This allows for optimization of selectivity parameters during synthesis while maintaining reasonable manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively stimulate angiogenic and erythropoietic responses, improving blood flow, oxygen delivery, and energy utilization in ischemic tissues, and treating conditions such as anemia and cardiovascular diseases.
Implementation Method 1
HIF-1 α under normal healthy conditions wherein the cells have a sufficient supply of oxygen is readily converted to a degraded form by one of several prolyl hydroxylase enzymes
Implementation Method 2
The substituted aryl or heteroaryl amide compounds of the present disclosure are a new class of compounds that can inhibit HIF-1α prolyl hydroxylase
Data Source
AI summary
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.